Indications › Chronic kidney disease › semaglutide
semaglutide in chronic kidney disease
semaglutide is approved in the US for chronic kidney disease, and has 10 trials on file here in this condition. 6 of them are phase 3 or later. The next scheduled result is 2026-09-30.
10 registered trials study semaglutide (Rybelsus, Wegovy, Ozempic) in chronic kidney disease, 6 of them still active. The next is due to report 2026-12-31.
- Trials on file
- 10
- Active
- 6
- Active phase 3
- 0
- Participants in active trials
- 970
- Sponsors
- 8
- Scheduled readouts
- 3
Scheduled to report
Dates are filed by the sponsor and move often. Each links to its own record and change history.
| Est. completion | Trial | Phase | Participants |
|---|---|---|---|
| 2026-12-31 | Sit Less, Interact and Move More (SLIMM) 2 Study NCT05173714 · Srinvasan Beddhu | P2 | 156 |
| 2027-07 | Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis NCT07017270 · Unity Health Toronto | P4 | 100 |
| 2028-06 | A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease NCT07239570 · Peter Rossing | P4 | 125 |
All trials on file
Every registered trial of semaglutide grouped under chronic kidney disease, largest first. Grouping follows the registry’s own condition wording.
See the full record for semaglutide, or every molecule being studied in chronic kidney disease. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.